New Leaf Fund Investment Strategy Overview for Late-Stage Biotech Companies
Summary
The passage outlines a private fund's investment focus on late‑stage biotech firms and lists several portfolio companies. It contains no direct references to high‑ranking officials, government agencie Fund targets companies nearing regulatory approval and commercial profitability. Focus on small‑cap public and private biotech firms with low clinical risk. Examples of past investments: Acadia Pharm
This document is from the House Oversight Committee Releases.
View Source CollectionPersons Referenced (1)
Tags
Related Documents (6)
New Leaf Venture Partners outlines investment strategy for NLV-III fund
The passage provides a standard venture capital fund investment overview with no mention of specific high‑profile individuals, government agencies, or controversial transactions. It lacks actionable l Fund targets biopharma, information convergence, medical devices, and research tools. Plans to invest in 24‑28 companies, primarily US‑based. Fund managers intend to serve on board seats and influenc
Series A and private equity funding announcements for various tech and consumer companies
The passage lists routine venture capital and private equity transactions without mentioning high‑profile officials, government agencies, or controversial financial flows. It provides no actionable le Gabi raised $9.5M Series A led by Canvas Ventures. Dover Microsystems secured $6M seed round with Qualcomm Ventures participation. Anyfin obtained $5.9M Series A led by Accel and Northzone.
Tax withholding and USRPHC rules for KUE limited partnership investors
The passage outlines standard tax compliance and reporting requirements for a private investment fund (KUE). It contains no references to high‑profile individuals, government agencies, or suspicious f Non‑U.S. limited partners may face U.S. federal income tax on gains from sale of LP units. Potential USRPHC status of KUE's U.S. subsidiaries could trigger additional tax liability. Backup withholdin
Blockchain Capital fund proposal targeting $10‑15M with 6‑8 year term
The passage is a basic term sheet for a private investment fund with no mention of high‑ranking officials, government agencies, or controversial transactions. It provides limited specifics (fund size, Fund target size: $10‑15 million Term length: 6‑8 years Management fee/incentive: 2.5% fee, 25% incentive
Series A and private equity funding announcements across tech and consumer sectors
The passage lists recent venture capital and private equity deals with no mention of high‑ranking officials, government agencies, or controversial transactions. It provides basic financial details use Gabi raised $9.5M Series A led by Canvas Ventures. Dover Microsystems secured $6M seed round with Qualcomm Ventures participation. Anyfin obtained $5.9M Series A led by Accel and Northzone.
Investment memorandum on patient engagement and pricing fraud mitigation technologies
The passage outlines private investment strategies in healthcare technology without mentioning any high‑profile officials, government agencies, or controversial financial flows. It provides no actiona Focus on low‑cost patient engagement platforms (e.g., Audax Health's Zensey). Emphasis on pricing transparency and fraud detection tools (e.g., Truveris). Strategy to take board seats in private U.S.
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.